Combination of treosulfan, fludarabine and cytarabine as conditioning in patients with acute myeloid leukemia, myelodysplastic syndrome and myeloproliferative neoplasms

[1] Arai Y(2015)Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy J Hematol Oncol 8 102-720

[2] Aoki K(2008)Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients Am J Hematol 83 717-241

[3] Takeda J(2005)Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications Bone Marrow Transplant 35 233-e39

[4] Kondo T(2020)Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial Lancet Haematol 7 e28-240

[5] Eto T(2016)Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis Bone Marrow Transplant 51 232-256

[6] Ota S(1996)Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside Invest New Drugs 14 249-662

[7] Baronciani D(2004)Treosulfan based conditioning for autologous and allogeneic hematopoietic stem cell transplantation Int J Clin Pharmacol Ther 42 661-731

[8] Rambaldi A(2004)Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation Blood 103 725-S71

[9] Iori AP(2004)Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation Ann Hematol 83 S70-3351

[10] Di Bartolomeo P(2010)Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning J Clin Oncol 28 3344-1177

[1] Arai Y(2015)Clinical significance of high-dose cytarabine added to cyclophosphamide/total-body irradiation in bone marrow or peripheral blood stem cell transplantation for myeloid malignancy J Hematol Oncol 8 102-720

[2] Aoki K(2008)Treosulfan/fludarabine as an allogeneic hematopoietic stem cell transplant conditioning regimen for high-risk patients Am J Hematol 83 717-241

[3] Takeda J(2005)Dose-escalated treosulphan in combination with cyclophosphamide as a new preparative regimen for allogeneic haematopoietic stem cell transplantation in patients with an increased risk for regimen-related complications Bone Marrow Transplant 35 233-e39

[4] Kondo T(2020)Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial Lancet Haematol 7 e28-240

[5] Eto T(2016)Busulfan fludarabine vs busulfan cyclophosphamide as a preparative regimen before allogeneic hematopoietic cell transplantation: systematic review and meta-analysis Bone Marrow Transplant 51 232-256

[6] Ota S(1996)Curative chemotherapy for acute myeloid leukemia: the development of high-dose ara-C from the laboratory to bedside Invest New Drugs 14 249-662

[7] Baronciani D(2004)Treosulfan based conditioning for autologous and allogeneic hematopoietic stem cell transplantation Int J Clin Pharmacol Ther 42 661-731

[8] Rambaldi A(2004)Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation Blood 103 725-S71

[9] Iori AP(2004)Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation Ann Hematol 83 S70-3351

[10] Di Bartolomeo P(2010)Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning J Clin Oncol 28 3344-1177